Dapagliflozin
- Generic Name
- Dapagliflozin
- Brand Names
- Edistride, Farxiga, Forxiga, Qtern, Qternmet, Xigduo, Dapagliflozin Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClO6
- CAS Number
- 461432-26-8
- Unique Ingredient Identifier
- 1ULL0QJ8UC
- Background
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosur...
- Indication
Dapagliflozin is indicated as an adjunct treatment to improve glycemic control in adult patients with type 2 diabetes mellitus along with diet and exercise.For patients with chronic kidney disease at risk of progression, dapagliflozin in used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and
...
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate, Hospitalization due to cardiac failure
- Associated Therapies
- -
Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?
- Conditions
- Interventions
- First Posted Date
- 2016-11-06
- Last Posted Date
- 2019-07-09
- Lead Sponsor
- University of Dundee
- Target Recruit Count
- 66
- Registration Number
- NCT02956811
- Locations
- 🇬🇧
Ninewells Hospital, Dundee, United Kingdom
Effect of Anti-diabetic Drugs on Glycemic Variability
- Conditions
- Interventions
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- Centro de Diabetes Curitiba Ltda
- Target Recruit Count
- 135
- Registration Number
- NCT02925559
- Locations
- 🇧🇷
Centro de Diabetes Curitiba, Curitiba, Parana, Brazil
Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration
- Conditions
- Interventions
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2023-11-30
- Target Recruit Count
- 72
- Registration Number
- NCT02911792
- Locations
- 🇺🇸
University Health Systems Texas Diabetic Institute, San Antonio, Texas, United States
🇺🇸The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
Effects of Dapagliflozin on Central Hemodynamics and Urine Albumin Excretion in Patients With Type 2 Diabetes.
- First Posted Date
- 2016-09-02
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- Hellenic Society for Medical Education
- Target Recruit Count
- 85
- Registration Number
- NCT02887677
- Locations
- 🇬🇷
Ahepa Hospital, Thessaloniki, Greece
🇬🇷Hippokrateio Hospital, Thessaloniki, Greece
🇬🇷Papageorgiou Hospital, Thessaloniki, Greece
HbA1c Variability in Type II Diabetes
- Conditions
- Interventions
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Weill Cornell Medical College in Qatar
- Target Recruit Count
- 150
- Registration Number
- NCT02879409
- Locations
- 🇶🇦
Hamad Medical Corporation, Doha, Qatar
Evaluation of the Tubular Effects of Dapagliflozin Using 1HNMR Spectroscopy
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2019-04-19
- Lead Sponsor
- University of Ioannina
- Target Recruit Count
- 50
- Registration Number
- NCT02798757
- Locations
- 🇬🇷
University of Ioannina, Ioánnina, Greece
Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes
- First Posted Date
- 2016-06-10
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- Tulane University School of Medicine
- Target Recruit Count
- 11
- Registration Number
- NCT02796170
- Locations
- 🇺🇸
Tulane University, New Orleans, Louisiana, United States
A Single-dose Cross-over Study to Assess Direct and Indirect Effects of Dapagliflozin on Pancreatic Alpha and Beta Cells in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2016-12-12
- Lead Sponsor
- Uppsala University
- Target Recruit Count
- 15
- Registration Number
- NCT02765204
- Locations
- 🇸🇪
Dept of Medical Sciences Uppsala University Hospital, Uppsala, Sweden
Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years
- Conditions
- Interventions
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2022-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 72
- Registration Number
- NCT02725593
- Locations
- 🇬🇧
Research Site, Leicester, United Kingdom
Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2
- Conditions
- Interventions
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2016-03-25
- Target Recruit Count
- 100
- Registration Number
- NCT02719756
- Locations
- 🇷🇺
Research Clinical Centre of the Russian Railways, JSC, Moscow, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.